Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,026.00+0.52%ETH$2,411.08+0.39%GOLD$4,309.20-1.78%OIL$101.99-0.43%
Smart Investors Daily
MD

NASDAQ · MDXG

MiMedx Group, Inc.

Healthcare · Biotechnology

$4.72

Up+$0.01 (+0.21%)

Updated Sep 16, 2026, 11:36 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.06B
P/E ratio
26
Dividend yield
0.00%
52-week range
$3.03 – $4.80
Volume
1.15M
Avg. volume
834.24K

Price performance

MDXG price history

1M range · 20 trading sessions · Daily adjusted prices

MDXG closed at $4.72 after 20 trading sessions, up 8.76% for the selected period.

Last close
$4.72
Period change
+8.76%
Period low
$4.27
Period high
$4.72
Daily close
View OHLC price history
MDXG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$4.64$4.795$4.58$4.721.15M
Sep 14, 2026$4.60$4.665$4.54$4.64888.92K
Sep 11, 2026$4.64$4.71$4.51$4.57995.85K
Sep 10, 2026$4.65$4.69$4.50$4.601.62M
Sep 9, 2026$4.64$4.70$4.56$4.681.05M
Sep 8, 2026$4.57$4.73$4.43$4.671.06M
Sep 4, 2026$4.41$4.585$4.41$4.57624.97K
Sep 3, 2026$4.54$4.61$4.345$4.43841.63K
Sep 2, 2026$4.52$4.71$4.52$4.551.04M
Sep 1, 2026$4.53$4.61$4.485$4.52762.37K
Aug 31, 2026$4.49$4.57$4.395$4.541.06M
Aug 28, 2026$4.49$4.635$4.48$4.50887.02K
Aug 27, 2026$4.45$4.76$4.45$4.511.18M
Aug 26, 2026$4.33$4.44$4.27$4.42711.03K
Aug 25, 2026$4.28$4.38$4.27$4.34700.02K
Aug 24, 2026$4.36$4.39$4.24$4.27846.66K
Aug 21, 2026$4.30$4.35$4.25$4.33897.11K
Aug 20, 2026$4.40$4.47$4.28$4.301.43M
Aug 19, 2026$4.37$4.50$4.365$4.451.16M
Aug 18, 2026$4.20$4.37$4.20$4.341.22M

Latest MDXG news

The latest Smart Investors Daily articles mentioning MDXG.

Stock researchCompany · Overview

MDXG research

Overview

Company profile and research snapshot.

Company profile

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$11.75
Implied upside
—
Analysts
—
MDXG recent ratings
DateFirmRatingTarget
Aug 27, 2026Craig-HallumBuy—
Aug 17, 2026Cantor FitzgeraldOverweight—
Apr 30, 2026CitizensMarket Outperform—
Apr 20, 2026CitizensMarket Outperform—
Apr 17, 2026Craig-HallumBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

MIMEDX to Participate in Upcoming Investor Conferences

MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Cantor Global Healthcare Conference | New York, NYWednesday, September 9, 20261:1 sessions Lake Street BIG10 Best Ideas Growth Conference | New York, NYThursday, September 10, 20261:1 sessions Investors interested in meeting with senior management at these events may contact th

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By